Asia Pacific Plasma Fractionation Market Overview and Growth by 2028

The plasma fractionation market in APAC is expected to grow from US$ 5,854.65 million in 2021 to US$ 9,433.53 million by 2028; it is estimated to grow at a CAGR of 7.1% from 2021 to 2028.

The supply chain disturbances and the tremendous demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the APAC region. Preventive measures have been taken to control the spread of this pandemic. The COVID-19 pandemic has broadly affected the economies in the APAC region. Countries such as India, China, Japan, and South Korea were adversely affected by the pandemic. The socioeconomics was severely affected, rising in negative inflation, GDPs, and a regional unemployment surge.Countries such as China, Japan, Singapore, and South Korea are seeing an increased interest in clinical trials. High costs in western countries are also contributing to the flow of medical affairs outsourcing to the APAC region. To expand sales to the Asian market, pharmaceutical companies are becoming aware of new and changing regulatory environments for drugs, devices, and in-vitro diagnostics. New or improved regulations are implemented frequently in Asia, including changes in GMP standards, drug price controls, and medical device regulatory systems. Third-party guidance and advice are required as a part of any acquisition or improvement of current standards. Increasingly, third-party outsourcing service providers are playing a more significant role in supporting the associated market in APAC. However, the market is stabilized compared to the initial phases of the pandemic, owing to the control procedures, awareness among people, availability of vaccinations, and supportive government policies of the business in the related market. 

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC plasma fractionation market. The APAC plasma fractionation market is expected to grow at a good CAGR during the forecast period.

 APAC Plasma FractionationMarket Revenue and Forecast to 2028 (US$ Million)

APAC Plasma Fractionation Market Segmentation

APAC Plasma Fractionation Market – By Product

• Immunoglobulin
  • Intravenous Immunoglobulin (IVIG)
  • Subcutaneous Immunoglobulin (SCIG)
• Albumin
• Coagulation Factor Concentrates
• Protease Inhibitors
• Other

APAC Plasma Fractionation Market – By Application

• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Others

APAC Plasma Fractionation Market – By End User

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes

APAC Plasma Fractionation Market, by Country

• Australia
• China
• India
• Japan
• South Korea
• Rest of APAC

APAC Plasma Fractionation Market - Companies Mentioned

• Bharat Serums and Vaccines Limited (BSV)
• Bio Products Laboratory Ltd.
• CSL Limited
• Grifols, S.A.
• Kedrion S.p.A
• Octapharma AG
• PlasmaGen Biosciences Pvt. Ltd.
• SK Plasma

Asia Pacific Plasma Fractionation Report Scope